DIABETIC MACULAR EDEMA (DME)
Clinical trials for DIABETIC MACULAR EDEMA (DME) explained in plain language.
Never miss a new study
Get alerted when new DIABETIC MACULAR EDEMA (DME) trials appear
Sign up with your email to follow new studies for DIABETIC MACULAR EDEMA (DME), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot in the eye aims to halt diabetic vision loss
Disease control Recruiting nowThis is an early safety study testing a single experimental injection (avoralstat) into the eye for people with diabetic macular edema (DME), a cause of vision loss. The main goal is to see if the injection is safe and tolerable. Researchers will also look for early signs that it…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE1 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New eye implant could drastically reduce injections for diabetic vision loss
Disease control Recruiting nowThis study is testing a new, long-acting eye implant called EYP-1901 against the standard aflibercept injections for diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The main goal is to see if the implant can control the disease just as well wh…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New eye implant could drastically reduce injections for diabetic vision loss
Disease control Recruiting nowThis study is testing if a new, long-acting eye implant called EYP-1901 can control vision loss from diabetic macular edema as well as standard aflibercept injections, but with far fewer treatments. It will involve about 240 adults with the condition, comparing the implant's effe…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Gene therapy trial offers hope for diabetic eye disease
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called LX111 for diabetic macular edema, a vision-threatening complication of diabetes. Researchers will give a single injection into the eye to 32 participants who have previously responded to standard anti-VEGF treatments. Th…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC